Tamara Slosarek

Tamara Slosarek

Auto-generated profile, based on publicly available information

Tamara Slosarek

University of Potsdam Hasso Plattner Institute for Digital Engineering Potsdam, 14482

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in JMIR Rehabilitation and Assistive Technologies
Verified
Journal Article
Open access
DLDaniel Lewkowicz
Daniel Lewkowicz
TSTamara Slosarek
Tamara Slosarek
SWSarah Wernicke
Sarah Wernicke
AWAntonia Winne
Antonia Winne
AWAttila M Wohlbrandt
Attila M Wohlbrandt
EBErwin Bottinger
Erwin Bottinger
Background: Low back pain (LBP) is the leading cause of worldwide years lost because of disability, with a tremendous economic burden for health care systems. Digital therapeutic care (DTC) programs provide a scalable, universally accessible, and low-cost approach to the multidisciplinary treatment of LBP. Moreover, novel decision support interventions such as personalized feedback messages, push notifications, and data-driven activity recommendations amplify DTC by guiding the user through the program while aiming to increase overall engagement and sustainable behavior change. Objective: This systematic review aims to synthesize recent scientific literature on the impact of DTC apps for people with LBP and outline the implementation of add-on decision support interventions, including their effect on user retention and attrition rates. Methods: We searched bibliographic databases, including MEDLINE, Cochrane Library, Web of Science, and the Physiotherapy Evidence Database, from March 1, 2016, to October 15, 2020, in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and conducted this review based on related previously published systematic reviews. Besides randomized controlled trials (RCTs), we also included study designs with the evidence level of at least a retrospective comparative study. This enables the consideration of real-world user-generated data and provides information regarding the adoption and effectiveness of DTC apps in a real-life setting. For the appraisal of the risk of bias, we used the Risk of Bias 2 Tool and the Risk of Bias in Non-Randomized Studies of Interventions Tool for the RCTs and nonrandomized trials, respectively. The included studies were narratively synthesized regarding primary and secondary outcome measures, DTC components, applied decision support interventions, user retention, and attrition rates. Results: We retrieved 1388 citations, of which 12 studies are included in this review. Of the 12 studies, 6 (50%) were RCTs and 6 (50%) were nonrandomized trials. In all included studies, lower pain levels and increased functionality compared with baseline values were observed in the DTC intervention group. A between-group comparison revealed significant improvements in pain and functionality levels in 67% (4/6) of the RCTs. The study population was mostly homogeneous, with predominantly female, young to middle-aged participants of normal to moderate weight. The methodological quality assessment revealed moderate to high risks of biases, especially in the nonrandomized trials. Conclusions: This systematic review demonstrates the benefits of DTC for people with LBP. There is also evidence that decision support interventions benefit overall engagement with the app and increase participants’ ability to self-manage their recovery process. Finally, including retrospective evaluation studies of real-world user-generated data in future systematic reviews of digital health intervention trials can reveal new insights into the benefits, challenges, and real-life adoption of DTC programs.

5 July 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SKStefan Konigorski
Stefan Konigorski
SWSarah Wernicke
Sarah Wernicke
TSTamara Slosarek
Tamara Slosarek
AZAlexander M Zenner
Alexander M Zenner
NSNils Strelow
Nils Strelow
EBErwin Böttinger
Erwin Böttinger
N-of-1 trials are the gold standard study design to evaluate individual treatment effects and derive personalized treatment strategies. Digital tools have the potential to initiate a new era of N-of-1 trials in terms of scale and scope, but fully functional platforms are not yet available. Here, we present the open source StudyU platform, which includes the StudyU Designer and StudyU app. With the StudyU Designer, scientists are given a collaborative web application to digitally specify, publish, and conduct N-of-1 trials. The StudyU app is a smartphone app with innovative user-centric elements for participants to partake in trials published through the StudyU Designer to assess the effects of different interventions on their health. Thereby, the StudyU platform allows clinicians and researchers worldwide to easily design and conduct digital N-of-1 trials in a safe manner. We envision that StudyU can change the landscape of personalized treatments both for patients and healthy individuals, democratize and personalize evidence generation for self-optimization and medicine, and can be integrated in clinical practice.

5 January 2021 in JMIR Preprints
Verified
Preprint
Open access
DLDaniel Lewkowicz
Daniel Lewkowicz
TSTamara Slosarek
Tamara Slosarek
SWSarah Wernicke
Sarah Wernicke
AWAntonia Winne
Antonia Winne
AWAttila M Wohlbrandt
Attila M Wohlbrandt
EBErwin Bottinger
Erwin Bottinger
BACKGROUND Low back pain (LBP) is the leading cause of worldwide years lost because of disability, with a tremendous economic burden for health care systems. Digital therapeutic care (DTC) programs provide a scalable, universally accessible, and low-cost approach to the multidisciplinary treatment of LBP. Moreover, novel decision support interventions such as personalized feedback messages, push notifications, and data-driven activity recommendations amplify DTC by guiding the user through the program while aiming to increase overall engagement and sustainable behavior change. OBJECTIVE This systematic review aims to synthesize recent scientific literature on the impact of DTC apps for people with LBP and outline the implementation of add-on decision support interventions, including their effect on user retention and attrition rates. METHODS We searched bibliographic databases, including MEDLINE, Cochrane Library, Web of Science, and the Physiotherapy Evidence Database, from March 1, 2016, to October 15, 2020, in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and conducted this review based on related previously published systematic reviews. Besides randomized controlled trials (RCTs), we also included study designs with the evidence level of at least a retrospective comparative study. This enables the consideration of real-world user-generated data and provides information regarding the adoption and effectiveness of DTC apps in a real-life setting. For the appraisal of the risk of bias, we used the Risk of Bias 2 Tool and the Risk of Bias in Non-Randomized Studies of Interventions Tool for the RCTs and nonrandomized trials, respectively. The included studies were narratively synthesized regarding primary and secondary outcome measures, DTC components, applied decision support interventions, user retention, and attrition rates. RESULTS We retrieved 1388 citations, of which 12 studies are included in this review. Of the 12 studies, 6 (50%) were RCTs and 6 (50%) were nonrandomized trials. In all included studies, lower pain levels and increased functionality compared with baseline values were observed in the DTC intervention group. A between-group comparison revealed significant improvements in pain and functionality levels in 67% (4/6) of the RCTs. The study population was mostly homogeneous, with predominantly female, young to middle-aged participants of normal to moderate weight. The methodological quality assessment revealed moderate to high risks of biases, especially in the nonrandomized trials. CONCLUSIONS This systematic review demonstrates the benefits of DTC for people with LBP. There is also evidence that decision support interventions benefit overall engagement with the app and increase participants’ ability to self-manage their recovery process. Finally, including retrospective evaluation studies of real-world user-generated data in future systematic reviews of digital health intervention trials can reveal new insights into the benefits, challenges, and real-life adoption of DTC programs.

21 December 2021 in JMIR Preprints
Verified
Preprint
Open access
SKStefan Konigorski
Stefan Konigorski
SWSarah Wernicke
Sarah Wernicke
TSTamara Slosarek
Tamara Slosarek
AZAlexander M Zenner
Alexander M Zenner
NSNils Strelow
Nils Strelow
EBErwin Böttinger
Erwin Böttinger
UNSTRUCTURED N-of-1 trials are the gold standard study design to evaluate individual treatment effects and derive personalized treatment strategies. Digital tools have the potential to initiate a new era of N-of-1 trials in terms of scale and scope, but fully functional platforms are not yet available. Here, we present the open source StudyU platform, which includes the StudyU Designer and StudyU app. With the StudyU Designer, scientists are given a collaborative web application to digitally specify, publish, and conduct N-of-1 trials. The StudyU app is a smartphone app with innovative user-centric elements for participants to partake in trials published through the StudyU Designer to assess the effects of different interventions on their health. Thereby, the StudyU platform allows clinicians and researchers worldwide to easily design and conduct digital N-of-1 trials in a safe manner. We envision that StudyU can change the landscape of personalized treatments both for patients and healthy individuals, democratize and personalize evidence generation for self-optimization and medicine, and can be integrated in clinical practice.

7 July 2026 in JAMIA Open
Verified
Journal Article
Open access
TSTamara Slosarek
Tamara Slosarek
JBJannis Baum
Jannis Baum
BFBenjamin Frost
Benjamin Frost
NGNikola Genchev
Nikola Genchev
LHLeon Hermann
Leon Hermann
AOAniwaa Owusu Obeng
Aniwaa Owusu Obeng
Objective: Pharmacogenomics can optimize therapeutic outcomes while minimizing adverse events. However, the lack of trained healthcare professionals has impeded its widespread adoption. Current patient-facing applications are either institution-specific or vary significantly in their coverage of genetic variants, interpretation guidelines, and data privacy protection. To address these shortcomings, we developed PharMe. Materials and Methods: All components were developed through co-design; experts created patient-friendly content in English from Clinical Pharmacogenomics Implementation Consortium and Food and Drug Administration guidelines. Results: PharMe returns pharmacogenomic results for 17 genes and 159 medications, including phenoconversion of CYP2D6 due to inhibitors. PharMe is facilitated by Anni, a web interface enabling consistent, multilingual annotation of guidelines with patient-friendly formulations. Initial evaluations demonstrate that PharMe is usable and stable. PharMe is available for iOS and Android in English. Discussion: PharMe and Anni use transparent, standardized guideline content, are agnostic to data sources, and can flexibly be deployed globally in different settings and institutions, while upholding data privacy. Prospectively, both could support further guidelines and data formats. Validation of clinical utility, patient comprehension, and empowerment is underway in a clinical validation study with diverse patients. Conclusion: We developed a novel, extensible, usable, and stable system to transparently return pharmacogenomic results to patients. These findings support further investigation in larger, more diverse populations and in real-world clinical settings, with the goal of informing scalable, guideline-concordant pharmacogenomics implementation.

20 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
TSTamara Slosarek
Tamara Slosarek
SISusanne Ibing
Susanne Ibing
BSBarbara Schormair
Barbara Schormair
HHHenrike O. Heyne
Henrike O. Heyne
EBErwin P. Böttinger
Erwin P. Böttinger
CSClaudia Schurmann
Claudia Schurmann
Purpose Due to the increasing application of genome analysis and interpretation in medical disciplines, professionals require adequate education. Here, we present the implementation of personal genotyping as an educational tool in two genomics courses targeting Digital Health students at the Hasso Plattner Institute (HPI) and medical students at the Technical University of Munich (TUM). Methods We compared and evaluated the courses and the students’ perceptions on the course setup using questionnaires. Results During the course, students changed their attitudes towards genotyping (HPI: 79% [15 of 19], TUM: 47% [25 of 53]). Predominantly, students became more critical of personal genotyping (HPI: 73% [11 of 15], TUM: 72% [18 of 25]) and a majority of students stated that genetic analyses should not be allowed without genetic counseling (HPI: 79% [15 of 19], TUM: 70% [37 of 53]). Students found the personal genotyping component useful (HPI: 89% [17 of 19], TUM: 92% [49 of 53]) and recommended its inclusion in future courses (HPI: 95% [18 of 19], TUM: 98% [52 of 53]). Conclusion Students perceived the personal genotyping component as valuable in the described genomics courses. The implementation described here can serve as an example for future courses in Europe.